Doctors stunned to see strict exercise regimen is as good as medicine for colon cancer
Scientists and doctors love to joke that exercise is a pretty great drug.
But can workouts really compete with chemotherapy to prevent a disease like recurrent colon cancer? That's been tough to prove — until now.
Results of the first randomized controlled trial of exercise as a treatment for recurrent high-risk cancer were presented at the American Society of Clinical Oncology's (ASCO) annual meeting in Chicago on June 1, and they stunned the crowd of doctors gathered there from around the world.
The 17-year trial included over 880 patients from around the globe, each recovering from high-risk stage 2 or stage 3 colon cancer after treatment. Half of the participants were given general advice about exercise and how it can improve cancer survival. The other half were given a structured, three-year exercise prescription to follow, with the goal of preventing recurrence or a new cancer diagnoses.
In the trial, exercise outperformed what adjuvant (or, secondary) chemotherapy can do to boost a patient's long-term survival, after surgery and primary treatment is over. Adjuvant cancer treatment is the kind designed to kill any extra cancer cells left behind, and prevent cancer from coming back.
"Exercise is no longer just an intervention that improves quality of life and fitness. It is a treatment," Chris Booth, the study's lead author and a medical oncologist at Queen's University in Ontario, told the crowd.
Brisk walking prevented recurrent colon cancer, plus new breast and prostate cases
In the study, patients who followed an exercise regimen reduced their risk of death by 37%, and reduced their risk of cancer recurrence and new cancer development by 28%.
The benefits of this three-year exercise prescription — which included advice and support from a trainer or physical therapist — were also long-lasting.
After eight years, 90% of patients in the exercise program were alive compared to 83% in the control group.
This 7% survival bump is comparable to (and in some cases exceeds) the survival benefits of standard drugs that doctors use in this same context. The common adjuvant chemotherapy drug oxaliplatin gives patients an overall survival boost of 5% after 10 years. Many other adjuvant cancer drugs deliver similar survival benefits, of around 5 to 10%.
The effect didn't seem to be due to other factors. Patients didn't lose weight or belly fat, and no meaningful difference was seen in fatal heart attacks. The exercisers also weren't turning into Olympic athletes; they were just doing the equivalent of about 1.5 to 2.25 extra hours of brisk walking each week.
In addition to reducing colon cancer diagnoses and deaths, the exercise also seemed to reduce the risk of other cancers. In the exercise group, there were two new cases of breast cancer diagnosed, compared to 12 cases among the controls.
Other cancer doctors at the conference were shocked at the magnitude of the effect even though they've always kind of known exercise is good for cancer. Exercise is generally recommended to patients in recovery to improve outcomes. But to beat standard chemotherapy drugs? That was impressive.
Dr. Paul Oberstein, a medical oncologist at NYU Langone who was not involved in the study, said he'd like to bring this treatment to his patients, maybe with some help from wearables like watches, and on-demand fitness classes people can access at home.
"If you could somehow package this and bill it as a drug, it would be very valuable because the benefit was really remarkable," he said.
Scientists are still figuring out why exercise is so great at preventing and treating cancer
Researchers are still studying the blood samples of patients who were in this study, drilling down into what might be driving the anti-cancer effects from exercise.
Oberstein suspects that exercise is probably doing something that's powerfully anti-inflammatory in the body, reducing tumor growth, and preventing cancer's spread. At least, that's what he observes when he studies mice on treadmills in his lab.
"Of course, mice on treadmills are not really people," he said, chuckling. "But what we see, and what we think might be applying, is that they have less inflammation."
Other researchers think that perhaps exercise is revving up the immune system, engaging in what's called "immune surveillance" against cancer.
"These are very hard things to measure over a long period of time," Oberstein said.
Booth, who's been an avid long-distance runner ever since he was a kid, said this treatment should now be offered to any recovering colon cancer patient who wants it.
"This intervention is empowering for patients, it is achievable for patients, and with a cost that is far lower than our standard," he said near the end of his talk.
Slowly, but surely, the whole crowd stood up and burst into a sustained and hearty standing ovation.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
2 days ago
- Medscape
ASCO 2025: New Standards Reshape Care in mBC
Heather McArthur, MD, describes how the 2025 ASCO Annual Meeting brought exciting advances in the metastatic breast cancer space. In PD-L1-positive triple-negative breast cancer, sacituzumab govitecan combined with pembrolizumab significantly improved progression-free survival over standard chemotherapy plus pembrolizumab, quickly becoming a new standard of care. Similarly, in HER2-positive disease, trastuzumab deruxtecan combined with pertuzumab outperformed traditional THP therapy, offering a new frontline option. Overall, these findings signify a major shift in how to treat metastatic breast cancer.
Yahoo
2 days ago
- Yahoo
Transgene completes initial screening in Phase II part of TG4050 vaccine trial
Transgene has completed the initial subject screening for the Phase II segment of its Phase I/II trial of individualised neoantigen therapeutic vaccine, TG4050, as a monotherapy in the adjuvant treatment of human papillomavirus (HPV)-negative squamous head and neck cancers. The vaccine is based on the myvac platform powered by its partner NEC's AI to enhance antigen selection. During the Phase I portion of the trial, all subjects treated with the vaccine remained disease-free post a minimum follow-up of two years, demonstrating clinical proof of principle. Translational data indicated that these subjects showed sustained T cell responses at 24 months. Meeting all trial endpoints, the findings were shared at the American Society of Clinical Oncology (ASCO 2025) annual meeting. The company anticipates completing the randomisation of all subjects in the Phase II part by the end of this year, after a second screening carried out post-surgery and adjuvant radiotherapy. Around 80 subjects who have completely responded to adjuvant therapy are expected to be enrolled and randomised in the Phase I/II trial. The first immunogenicity data from the Phase II part are projected to be available in the second half of 2026, with preliminary efficacy data anticipated in the second half of 2027. The trial is assessing the treatment benefits of the vaccine in individuals at risk of relapse. So far, 32 evaluable patients have been included in the Phase I part, with the Phase II continuing globally. Transgene chief medical officer Dr Emmanuelle Dochy said: 'Timely completion of first patient screening of the Phase II part of our Phase I/II trial is an important milestone for Transgene and brings us one step closer to providing a new treatment option for patients living with operable squamous head and neck cancer. 'With meaningful data readouts expected over the next two years, we are preparing to deliver important data for TG4050 and, at the same time, explore its wider potential. We are grateful to the patients, their families, investigators, and clinical staff whose commitment made this achievement possible.' "Transgene completes initial screening in Phase II part of TG4050 vaccine trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Medscape
2 days ago
- Medscape
Oseltamivir Decreases Hospital Mortality Risk of Influenza
Treating patients with severe influenza with oseltamivir in the first 2 days after hospital admission was associated with a lower in-hospital mortality risk, earlier discharge, and lower readmission rate compared with supportive care, new data indicated. The additional evidence supports current guideline recommendations to treat all people hospitalized with influenza with an antiviral agent, regardless of how long they have been ill. The study, led by Anthony D. Bai, MD, assistant professor of infectious diseases at Queen's University in Kingston, Ontario, was published on June 10 in JAMA Network Open. Reduced Mortality Risk Each year, influenza causes 12,200 hospitalizations and 3500 deaths in Canada. It causes between 140,000 and 810,000 hospitalizations and 12,000 to 61,000 deaths in the United States. And despite guidelines in both countries that recommend treatment for all entering the hospital with influenza, clinical practice varies widely, Bai told Medscape Medical News . The researchers' study found that in Ontario, 30% of clinicians were not treating this population with oseltamivir. Researchers examined data from the General Medicine Inpatient Initiative database, which includes internal medicine and intensive care unit (ICU) patients admitted to participating hospitals in Ontario. Data included demographics, diagnoses, interventions, discharge, readmission, medication orders, and bloodwork results. The cohort study included 11,073 patients (average age, 72.6 years). Researchers found an adjusted risk reduction of 1.8% for in-hospital mortality when oseltamivir was given, compared with supportive care median length of stay was 4.4 days and 4.9 days in the oseltamivir and supportive care groups, respectively. After discharge, 645 patients (8.5%) in the oseltamivir group and 336 patients (9.8%) in the supportive care group were readmitted, with an adjusted risk difference of -1.5%. 'Some clinicians believe there won't be much benefit to treatment with oseltamivir,' said Bai, likely because of the dearth of evidence supporting the guidelines. 'There's been a lot of controversy about the benefit of oseltamivir in the outpatient population, where a recent meta-analysis showed it didn't really prevent hospitalizations. But there is a signal that it decreased in-hospital mortality. If a similar benefit is proven in a future randomized, controlled trial, it would add a lot of convincing evidence that there's a significant benefit to oseltamivir treatment.' The expanded version of the large RECOVERY randomized, controlled trial in the United Kingdom looks at that question, he noted. But until results are available, 'we should go by the current guideline recommendations.' Remaining Questions Wendy Sligl, MD, professor of critical care medicine and infectious diseases at the University of Alberta in Edmonton, told Medscape Medical News that the 1.8% in-hospital mortality reduction may seem small. 'Keep in mind, this is in all hospitalized patients, which includes a spectrum of disease severity from those not needing supplemental oxygen to those on a ventilator.' She pointed out that less than 10% of the patients in this study were admitted to the ICU. The number needed to treat is an important consideration with these results, she pointed out. 'Given this mortality reduction, you would need to treat approximately 55 patients to prevent one death. When the outcome is as devastating as death, and the drug is relatively safe and inexpensive, treatment seems reasonable, given even a small reduction in mortality.' Sligl also noted the need for high-quality evidence from randomized, controlled trials, including RECOVERY, in hospitalized patients with influenza. 'In addition, the most severe patients, those in the ICU with respiratory failure requiring high-flow oxygen or mechanical ventilation, should be specifically studied.' Beyond whether antiviral therapy is beneficial, she said, other questions remain, such as which antiviral is best and at what dose and duration. Other questions include whether an antiviral therapy should be used alone or in combination with another antiviral therapy and at what time in which patients. 'The best quality data we have for the treatment of influenza are in healthy outpatients, where treatment has been shown to reduce symptom severity and duration. Data for antiviral use in hospitalized patients with influenza are largely observational, suggesting a small mortality benefit with treatment,' Sligl explained. In the current study, she noted, 'target trial emulation with propensity scoring helped to minimize bias, which is a methodologic strength.' No funding source for this study was reported. Bai and Sligl reported having no relevant financial relationships.
